Navigation Links
Celtaxsys Restructures, Enhances Operational Focus
Date:9/9/2013

ATLANTA, Sept. 9, 2013 /PRNewswire/ -- Celtaxsys, Inc., an Atlanta-based pharmaceutical discovery and development company, announced today that it has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease.

As part of the restructuring, Dr. Michael Hanley has retired from his role as CEO and Chairman, and Dr. Brett Premack has stepped down as CTO.  Dr. H. Daniel Perez, a member of the Celtaxsys Board and former CEO of Berlex Biosciences and Presidio Pharmaceuticals, is serving as Chairman.

"We thank Dr. Hanley for his services as CEO and Chairman. Under his guidance, Celtaxsys has transformed into an exciting drug development company with a promising lead compound," said Dr. Perez.

In conjunction with these management changes, Celtaxsys is strengthening its clinical operations including bringing on Ed Philpot, MD, MBA, as CMO. Dr. Philpot has been serving as chair of the Medical Advisory Panel for the CTX-4430 development program for the past year and was formerly CMO at Smith & Nephew and prior to that Executive Director of Pulmonary Disease and Immuno-Inflammation at GSK, where he led several late stage clinical development programs. Celtaxsys has also expanded its internal Quality Assurance and Clinical Operations with additional key hires.

"We're excited to be able to bring more top talent into Celtaxsys," said Mike Masters, Celtaxsys Board Member. "As we continue to meet our clinical milestones, these changes demonstrate our strong support for the company and its programs".

About Cystic Fibrosis: Cystic Fibrosis is the most common life-shortening autosomal recessive disease among Caucasians, and lung disease is the leading cause of hospitalizations and death in adult CF patients. A hallmark of CF lung disease is excessive recruitment of blood polymorphonuclear neutrophils (PMNs) into the small airways (bronchioles) causing inflammation that results in elastic tissue destruction and progressive loss of lung function.

About CTX-4430: CTX-4430 is a once-daily oral drug candidate currently undergoing clinical trials for treatment of CF lung disease. It is a novel small molecule inhibitor of Leukotriene A4 Hydrolase (LTA4H), the key enzyme in production of the potent inflammatory mediator Leukotriene B4 (LTB4). LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in CF.

About Celtaxsys: Celtaxsys is a privately-held clinical stage drug discovery and development company focused on developing new treatments for inflammatory diseases by modulating innate immunity. The company is building a pipeline of first-in-class drugs with novel mechanisms of action. For more information, please visit www.celtaxsys.com.


'/>"/>
SOURCE Celtaxsys
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MDHI Enhances Service Offerings with New Options for Customers of Americas Largest Warehouse Club Chain - Announces New Extended Concierge Services
2. Marken Enhances Branch Operations
3. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
4. Virtua Enhances Efficiency with Integrated Identity and Access Management Solutions from Caradigm
5. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
6. Ekahau Enhances Real-Time Location System to Offer 20x More Scalability and Enhanced Reliability
7. NorDx Enhances Clinical Laboratory Diagnostic Services with State-of-the-Art Technology
8. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
9. SynteractHCR Enhances Adaptive Trial Capabilities
10. CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager
11. Pharmacists: Senate Bill Enhances Drug Supply Chain Security, but also Threatens Patient Access to Essential Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 LG Innotek today announced that the company ... As its sterilization performance is 1.5 times higher than the competitor,s ... rays in the range of 200 -- 280nm, allowing it to be ... destroying their DNA. LG Innotek,s product emits UV in the range ... Until ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Cardiac Prosthetic Devices Market is ... next decade to reach approximately $8.9 billion by 2025. ... the given segments on global as well as regional levels presented ...
(Date:2/23/2017)... February 23, 2017 Tillotts Pharma ... Berlin office was opened in ... . The portfolio includes Entocort ® for the ... treatment of ulcerative colitis, and VistaPrep ® for ... Swiss specialty pharmaceutical company focused on the treatment of ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and ... they are sponsoring a raffle. Throughout the month of February, patients who visit Hamlin ... gift card for a dinner for two at the Cheesecake Factory. , Tickets ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Dr. David Mahon ... Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson ... is an online directory that recognizes local physicians and dentists who have earned high ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... community for those in the fight against cancer, has produced a seminal study ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... program today with a new Indiegogo campaign . Individuals are now able to ... the Los Angeles area, either as a participating patient or through an Indiegogo donation. ...
(Date:2/23/2017)... ... 23, 2017 , ... Carlos Gutierrez has lived his spiritual life ... evolve, which is the purpose of everyone in this universe. As Gutierrez sees the ... Balboa Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual ...
Breaking Medicine News(10 mins):